ORG Wealth Partners LLC Invests $235,000 in Illumina, Inc. (NASDAQ:ILMN)

ORG Wealth Partners LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,803 shares of the life sciences company’s stock, valued at approximately $235,000.

Several other large investors have also bought and sold shares of the company. Procyon Advisors LLC boosted its stake in Illumina by 24.5% during the third quarter. Procyon Advisors LLC now owns 14,134 shares of the life sciences company’s stock valued at $1,843,000 after buying an additional 2,778 shares in the last quarter. Compagnie Lombard Odier SCmA boosted its position in shares of Illumina by 2,013.3% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 1,585 shares of the life sciences company’s stock valued at $207,000 after purchasing an additional 1,510 shares during the period. Douglas Lane & Associates LLC boosted its position in shares of Illumina by 12.9% in the 3rd quarter. Douglas Lane & Associates LLC now owns 290,345 shares of the life sciences company’s stock valued at $37,864,000 after purchasing an additional 33,272 shares during the period. Burns Matteson Capital Management LLC boosted its position in shares of Illumina by 58.1% in the 3rd quarter. Burns Matteson Capital Management LLC now owns 3,355 shares of the life sciences company’s stock valued at $438,000 after purchasing an additional 1,233 shares during the period. Finally, Gateway Investment Advisers LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $3,556,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ILMN. Daiwa America upgraded Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th. StockNews.com started coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, July 10th. Finally, TD Cowen upgraded Illumina from a “hold” rating to a “buy” rating and raised their price objective for the stock from $126.00 to $144.00 in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.05.

Illumina Stock Up 2.4 %

Shares of ILMN stock opened at $149.07 on Tuesday. The stock’s 50 day simple moving average is $130.87 and its 200 day simple moving average is $120.72. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $150.80. The company has a market capitalization of $23.75 billion, a price-to-earnings ratio of -18.29 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company’s revenue was down 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 EPS. As a group, research analysts predict that Illumina, Inc. will post 3.63 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.